Advertisement

Uterine Cancer

  • Amit Patel
Chapter

Abstract

Endometrial cancer is the most common gynaecological cancer in the UK with rates rising steadily over the last four decades. Fortunately majority of them are diagnosed in early stages with good prognosis. A pathway to diagnosis is governed by NICE guidance and treatment by BGCS guideline. Assessment of suspected and treatment of confirmed endometrial cancer has several areas of heterogeneity due to the lack of clear evidence. Knowing the absolute musts and formulating the best strategies for the areas of grey evidence would offer best protection against potential litigations. In addition to these clinical pitfalls, importance of due diligence in communication and documentation has never been of a greater importance.

Keywords

Endometrial cancer Clinical governance Patient safety Medical negligence Litigations 

References

  1. 1.
  2. 2.
    National Institute for Health and Care Excellence (NICE). Suspected cancer: recognition and referral. NICE Guideline; 2015. http://www.nice.org.uk/guidance/ng12. Accessed Oct 2017.
  3. 3.
    British Gynaecological Cancer Society (BGCS). Uterine Cancer Guidelines: Recommendations for Practice; 2017.https://bgcs.org.uk/BGCS%20Endometrial%20Guidelines%202017.pdf. Accessed Oct 2017.
  4. 4.
    Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009;373(9658):125–36.CrossRefPubMedGoogle Scholar
  5. 5.
    Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92(3):744–51.CrossRefPubMedGoogle Scholar
  6. 6.
    Frost JA, Webster KE, Bryant A, Morrison J. Lymphadenectomy for the management of endometrial cancer. Cochrane Database Syst Rev. 2017;(10). Art. No.: CD007585.Google Scholar
  7. 7.
    Todo Y, Kato H, Kaneuchi M, Watari H, Takeda M, Sakuragi N. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): A retrospective cohort analysis. (Published erratum appears in Lancet 2010; 376: 594.). Lancet. 2010;375:1165–72.CrossRefPubMedGoogle Scholar
  8. 8.
    Royal College of Obstetricians and Gynaecologists (RCOG), Sentinel Lymph Node Biopsy in Endometrial Cancer: Scientific Impact Paper No. 51; 2016. https://www.rcog.org.uk/en/guidelines-research-services/guidelines/sip51/. Assessed Oct 2017.
  9. 9.
    Rossi EC, Kowalski LD, Scalici J, et al. A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. Lancet Oncol. 2017;18:384–92.CrossRefPubMedGoogle Scholar
  10. 10.
    Royal College of Obstetricians and Gynaecologists (RCOG)/British Society of Gynaecological Endoscopy (BSGE) Joint Guideline Management of Endometrial Hyperplasia, Green-top Guideline No. 67; 2016. https://www.rcog.org.uk/globalassets/documents/guidelines/green-top-guidelines/gtg_67_endometrial_hyperplasia.pdf. Assessed Oct 2017.

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.University Hospitals Bristol NHS TrustBristolUK

Personalised recommendations